Lonicera japonica

Drug Profile

Lonicera japonica

Alternative Names: Flos Lonicerae Japonicae - Green Cross Corporation; GC-6101A; Japanese honeysuckle - Green Cross Corporation; Lonicera japonica THUNB - Green Cross Corporation; Lonicerae flos - Green Cross Corporation

Latest Information Update: 29 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Green Cross
  • Class Kampo medicine; Traditional-Chinese-medicine
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Gastritis

Most Recent Events

  • 29 Jul 2016 Lonicera japonica is still in phase II trials for Gastritis in South Korea (PO) (NCT02353039)
  • 01 Sep 2014 Phase-II clinical trials in Gastritis in South Korea (PO)
  • 23 Aug 2013 Preclinical trials in Gastritis in South Korea (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top